Kabra Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE323K01017
  • NSEID:
  • BSEID: 524322
INR
18.61
-0.97 (-4.95%)
BSENSE

Nov 20

BSE+NSE Vol: 55.32 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 271637,
    "name": "Kabra Drugs",
    "stock_name": "Kabra Drugs",
    "full_name": "Kabra Drugs Ltd",
    "name_url": "stocks-analysis/kabra-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "18.61",
    "chg": -0.97,
    "chgp": "-4.95%",
    "dir": -1,
    "prev_price": "19.58",
    "mcapval": "47.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524322,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE323K01017",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "55.32 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/kabra-drugs-271637-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Kabra Drugs Ltd Falls to 52-Week Low of Rs 15.25 Amidst Divergent Financial Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/kabra-drugs-ltd-stock-falls-to-52-week-low-of-rs1525-4250818",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/KabraDrugsLtd_priceRelatedfactors_4250818.png",
        "date": "2026-11-04 12:05:35",
        "description": ""
      },
      {
        "title": "Kabra Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/kabra-drugs-ltd-is-rated-sell-by-marketsmojo-4235235",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/KabraDrugsLtd_mojoScore_4235235.png",
        "date": "2026-10-23 10:10:03",
        "description": "Kabra Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 October 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Kabra Drugs Ltd Falls to 52-Week Low of Rs 16.99 Amidst Mixed Financial Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/kabra-drugs-ltd-stock-hits-52-week-low-amidst-continued-downtrend-4232202",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/KabraDrugsLtd_priceRelatedfactors_4232202.png",
        "date": "2026-10-21 10:39:06",
        "description": "A four-day losing streak has dragged Kabra Drugs Ltd down to a fresh 52-week low of Rs 16.99 on 21 Oct 2026, marking a 6.29% decline over this period despite the broader market showing resilience."
      },
      {
        "title": "Kabra Drugs Ltd Falls to 52-Week Low of Rs 17 as Sell-Off Deepens",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/kabra-drugs-ltd-stock-falls-to-52-week-low-of-rs17-amidst-bearish-trends-4226799",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/KabraDrugsLtd_priceRelatedfactors_4226799.png",
        "date": "2026-10-15 11:05:10",
        "description": "A sharp decline of 3.64% today dragged Kabra Drugs Ltd to a fresh 52-week low of Rs 17, marking a significant setback despite recent positive earnings momentum."
      },
      {
        "title": "Kabra Drugs Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/kabra-drugs-ltd-is-rated-sell-4208549",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/KabraDrugsLtd_mojoScore_4208549.png",
        "date": "2026-09-29 10:10:03",
        "description": "Kabra Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 September 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Kabra Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/kabra-drugs-ltd-is-rated-sell-by-marketsmojo-4197400",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/KabraDrugsLtd_mojoScore_4197400.png",
        "date": "2026-09-18 10:10:03",
        "description": "Kabra Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 September 2026, providing investors with the most recent insights into the company’s performance and outlook."
      }
    ],
    "total": 18,
    "sid": "271637",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/kabra-drugs-271637"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Nov-2026",
      "details": "Newspaper Advertisement for the quarter ended 30-September-2026",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter Ended 30-September-2026",
      "datetime": "06-Nov-2026",
      "details": "Financial Results for the quarter ended 30-September-2026.",
      "source": "BSE"
    },
    {
      "caption": "Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations 2015 For The Quarter Ended On 30Th September 2026",
      "datetime": "06-Nov-2026",
      "details": "Undertaking for Non-Applicability of Regulation 32 of SEBI (LODR)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Nov-2026 | Source : BSE

Newspaper Advertisement for the quarter ended 30-September-2026

Financial Results For The Quarter Ended 30-September-2026

06-Nov-2026 | Source : BSE

Financial Results for the quarter ended 30-September-2026.

Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations 2015 For The Quarter Ended On 30Th September 2026

06-Nov-2026 | Source : BSE

Undertaking for Non-Applicability of Regulation 32 of SEBI (LODR)

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available